Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
| Title: | Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. |
|---|---|
| Authors: | Ching THW; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Amoroso L; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Bohner C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; D'Amico E; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Eilbott J; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Entezar T; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Fitzpatrick M; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Fram G; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Grazioplene R; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Hokanson J; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Kichuk SA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Martins B; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Patel P; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Schaer H; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Shnayder S; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Witherow C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Pittenger C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Department of Psychology, Yale University, New Haven, CT, United States.; Center for Brain and Mind Health, Yale University School of Medicine, New Haven, CT, United States.; Child Study Center, Yale University School of Medicine, New Haven, CT, United States.; Kelmendi B; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. |
| Source: | Frontiers in psychiatry [Front Psychiatry] 2024 Jan 09; Vol. 14, pp. 1278823. Date of Electronic Publication: 2024 Jan 09 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Switzerland : Frontiers Research Foundation, 2010- |
| Abstract: | Background: To date, few randomized controlled trials of psilocybin with non-directive support exist for obsessive-compulsive disorder (OCD). Results and participant feedback from an interim analysis of an ongoing single-dose trial (NCT03356483) converged on the possibility of administering a higher fixed dose and/or more doses of psilocybin in future trials for presumably greater benefits.; Objectives: This trial aims to evaluate the safety, feasibility, tolerability, and clinical effects of two doses of psilocybin paired with non-directive support in the treatment of OCD. This trial also seeks to examine whether two doses of psilocybin lead to greater OCD symptom reduction than a single dose, and to elucidate psychological mechanisms underlying the effects of psilocybin on OCD.; Design: A randomized (1:1), waitlist-controlled design with blinded ratings will be used to examine the effects of two doses of oral psilocybin paired with non-directive support vs. waitlist control on OCD symptoms. An adaptive dose selection strategy will be implemented (i.e., first dose: 25 mg; second dose: 25 or 30 mg).; Methods and Analysis: This single-site trial will enroll 30 adult participants with treatment-refractory OCD. Aside from safety, feasibility, and tolerability metrics, primary outcomes include OCD symptoms assessed on the Yale-Brown Obsessive-Compulsive Scale - Second Edition (Y-BOCS-II). A blinded independent rater will assess primary outcomes at baseline and the primary endpoint at the end of the second dosing week. Participants will be followed up to 12 months post-second dosing. Participants randomized to waitlist will be rescreened after 7 weeks post-randomization, and begin their delayed treatment phase thereafter if still eligible.; Ethics: Written informed consent will be obtained from participants. The institutional review board has approved this trial (protocol v. 1.7; HIC #2000032623).; Discussion: This study seeks to advance our ability to treat refractory OCD, and catalyze future research seeking to optimize the process of psilocybin treatment for OCD through understanding relevant psychological mechanisms.Clinical trial registration: ClinicalTrials.gov, identifier NCT05370911.; (Copyright © 2024 Ching, Amoroso, Bohner, D’Amico, Eilbott, Entezar, Fitzpatrick, Fram, Grazioplene, Hokanson, Kichuk, Martins, Patel, Schaer, Shnayder, Witherow, Pittenger and Kelmendi.) |
| Competing Interests: | TC serves as a continuing faculty member in the Psychedelic-Assisted Therapy Training Program offered by Integrative Psychiatry Institute (IPI), and consults for Transcend Therapeutics. CP serves/has served as a consultant for Biohaven, Teva, Lundbeck, Brainsway, Ceruvia Lifesciences, Transcend Therapeutics, Nobilis Therapeutics, and Freedom Biotech, receives royalties and/or honoraria from Oxford University Press and Elsevier, and has filed a patent on the use of neurofeedback in the treatment of anxiety, which is not relevant to the current work. BK is co-founder and Chief Scientific Advisor for Transcend Therapeutics and has consulted for Ceruvia Lifesciences and Lobe Sciences. CP and BK have filed a patent on the use of psilocybin in the treatment of obsessive-compulsive disorder (#US17/466,111). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| Comments: | Erratum in: Front Psychiatry. 2024 Feb 16;15:1372373. doi: 10.3389/fpsyt.2024.1372373.. (PMID: 38435972) |
| References: | Expert Opin Drug Saf. 2022 Jun;21(6):833-840. (PMID: 35225143); Br J Clin Psychol. 2008 Nov;47(Pt 4):451-5. (PMID: 18573227); Int Clin Psychopharmacol. 2013 Jul;28(4):200-5. (PMID: 23587985); Expert Rev Neurother. 2013 Feb;13(2):187-202; quiz 203. (PMID: 23368806); Mol Psychiatry. 2010 Jan;15(1):53-63. (PMID: 18725912); J Psychopharmacol. 2008 Aug;22(6):621-32. (PMID: 18593735); JAMA Psychiatry. 2021 May 1;78(5):481-489. (PMID: 33146667); Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001765. (PMID: 18253995); J Psychopharmacol. 2021 Apr;35(4):437-446. (PMID: 33427007); CNS Spectr. 2022 Jul 11;:1-11. (PMID: 35811423); Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. (PMID: 24444771); Front Psychiatry. 2019 Nov 11;10:814. (PMID: 31824345); J Neurol Neurosurg Psychiatry. 2022 Sep 20;:. (PMID: 36127157); J Psychopharmacol. 2021 Apr;35(4):319-352. (PMID: 33174492); J Anxiety Disord. 2021 Jun;81:102407. (PMID: 33915506); J Obsessive Compuls Relat Disord. 2020 Jan;24:100498. (PMID: 32140386); J Clin Psychiatry. 2016 May;77(5):e605-11. (PMID: 27249090); J Clin Psychol. 2006 Dec;62(12):1445-67. (PMID: 17019673); J Pers. 1994 Dec;62(4):616-40. (PMID: 7861307); Behav Res Ther. 2003 Aug;41(8):863-78. (PMID: 12880642); J Psychopharmacol. 2015 Nov;29(11):1182-90. (PMID: 26442957); Int J Neuropsychopharmacol. 2002 Jun;5(2):181-91. (PMID: 12135542); Arch Gen Psychiatry. 1989 Nov;46(11):1006-11. (PMID: 2684084); Clin Psychol Rev. 2015 Aug;40:156-69. (PMID: 26117062); Depress Anxiety. 2010 May;27(5):470-5. (PMID: 20455248); Psychol Assess. 2010 Jun;22(2):223-32. (PMID: 20528050); Front Hum Neurosci. 2016 Jun 14;10:269. (PMID: 27378878); J Psychopharmacol. 2011 Nov;25(11):1434-52. (PMID: 20855349); Assessment. 2018 Jan;25(1):3-13. (PMID: 26988404); CNS Drugs. 2013 May;27(5):367-83. (PMID: 23580175); J Psychopharmacol. 2019 Sep;33(9):1076-1087. (PMID: 31294673); N Engl J Med. 2022 Nov 3;387(18):1637-1648. (PMID: 36322843); Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. (PMID: 16826400); World Psychiatry. 2013 Jun;12(2):137-48. (PMID: 23737423); Br J Psychiatry. 1979 Apr;134:382-9. (PMID: 444788); J Psychiatr Ment Health Nurs. 2011 Oct;18(8):744-50. (PMID: 21896118); Acta Psychiatr Scand. 2018 Nov;138(5):368-378. (PMID: 29923178); Curr Psychiatry Rep. 2012 Jun;14(3):211-9. (PMID: 22527872); Compr Psychiatry. 2021 Apr;106:152223. (PMID: 33618297); Br J Addict. 1991 Sep;86(9):1119-27. (PMID: 1932883); Acta Psychiatr Scand. 2021 Feb;143(2):101-118. (PMID: 33125716); CNS Spectr. 2013 Feb;18(1):21-33. (PMID: 23279901); J Psychiatr Res. 2023 May;161:364-370. (PMID: 37004409); J Clin Psychiatry. 2006 Nov;67(11):1735-40. (PMID: 17196053); Psychol Assess. 2010 Mar;22(1):180-98. (PMID: 20230164); J Psychopharmacol. 2016 Dec;30(12):1259-1267. (PMID: 27852960); Behav Res Ther. 2005 Nov;43(11):1527-42. (PMID: 16299894); J Psychopharmacol. 2021 Apr;35(4):353-361. (PMID: 33611977); Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53. (PMID: 17849776); CNS Drugs. 2022 Jan;36(1):17-30. (PMID: 34791625); Eur Addict Res. 2005;11(1):22-31. (PMID: 15608468); Psychiatry Res. 2022 Jun;312:114567. (PMID: 35490573); Clin Trials. 2012 Dec;9(6):767-76. (PMID: 23169874); Front Psychiatry. 2021 Aug 11;12:707057. (PMID: 34456763); Front Psychiatry. 2023 Apr 25;14:1178529. (PMID: 37181888); Psychiatry Res. 2015 May 30;227(1):104-13. (PMID: 25937054); Front Pharmacol. 2018 Nov 02;9:897. (PMID: 30450045); Psychopharmacology (Berl). 2004 Mar;172(2):145-56. (PMID: 14615876); J Psychopharmacol. 2016 Dec;30(12):1279-1295. (PMID: 27856683); Sci Rep. 2017 Oct 13;7(1):13187. (PMID: 29030624); Transcult Psychiatry. 2022 Oct;59(5):652-664. (PMID: 33499762); J Anxiety Disord. 2013 Mar;27(2):231-9. (PMID: 23511304); Arch Gen Psychiatry. 1989 Nov;46(11):1012-6. (PMID: 2510699); J Psychopharmacol. 2011 Nov;25(11):1453-61. (PMID: 21956378); J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73. (PMID: 2768151); Neuropsychopharmacology. 2020 Dec;45(Suppl 1):170-277. (PMID: 33279935); Depress Anxiety. 2013 Aug;30(8):716-22. (PMID: 23532944); Depress Anxiety. 2018 Jun;35(6):502-514. (PMID: 29451967); Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84. (PMID: 22865617); Int Rev Psychiatry. 2018 Aug;30(4):331-342. (PMID: 30260256); Aust N Z J Psychiatry. 2013 Feb;47(2):121-41. (PMID: 23125399) |
| Grant Information: | K23 MH122777 United States MH NIMH NIH HHS |
| Contributed Indexing: | Keywords: adult psychiatry; mental health; non-directive support; obsessive-compulsive disorder; psilocybin; psychedelic; treatment; waitlist |
| Molecular Sequence: | ClinicalTrials.gov NCT05370911 |
| Entry Date(s): | Date Created: 20240124 Latest Revision: 20240304 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10803438 |
| DOI: | 10.3389/fpsyt.2023.1278823 |
| PMID: | 38264632 |
| Database: | MEDLINE |
Journal Article